临床前模型中膳食omega-3多不饱和脂肪酸、肥胖和肠道微生物群之间的相互作用:随机对照试验的系统综述

IF 5.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Bing Cao, Yutong Sun, Chifong Lam, Yalin Chen, Christine E Dri, Roger S McIntyre
{"title":"临床前模型中膳食omega-3多不饱和脂肪酸、肥胖和肠道微生物群之间的相互作用:随机对照试验的系统综述","authors":"Bing Cao, Yutong Sun, Chifong Lam, Yalin Chen, Christine E Dri, Roger S McIntyre","doi":"10.1111/dom.16535","DOIUrl":null,"url":null,"abstract":"<p><p>Emerging research underscores the potential of omega-3 polyunsaturated fatty acids (PUFAs) in weight reduction and modulation of the gut microbiota. The current review systematically examines the effects of omega-3 PUFA supplementation on body weight regulation and gut microbiota modulation in high-fat diet (HFD)-induced obesity models. The study protocol was registered with PROSPERO (CRD42024559835). Systematic searches were conducted from database inception to May 2025 on PubMed/Embase, Web of Science and selected reference lists. A total of 32 trials were included, with 25 studies employing a HFD along with dietary omega-3 PUFA supplementation and 7 studies with a HFD prior to dietary omega-3 PUFA supplementation. Omega-3 PUFA interventions consistently demonstrated attenuation of HFD-induced weight gain and adiposity, though body weight remained elevated compared to low-fat diet controls. Omega-3 PUFA supplementation also induced significant gut microbiota compositional changes. Specifically, omega-3 PUFAs effectively reduced the Firmicutes/Bacteroidetes (F/B) ratio, reversing a hallmark feature of HFD-induced dysbiosis. Enrichment of beneficial taxa, such as Akkermansia muciniphila, Bifidobacterium and Lactobacillus, was consistently observed, correlating with enhanced short-chain fatty acid (SCFA) production, improved gut barrier integrity and reduced systemic inflammation. Concurrently, omega-3 PUFAs suppressed pathogenic bacteria, such as Desulfovibrio and Lachnoclostridium, which are associated with endotoxaemia and metabolic dysfunction. These preclinical evidence suggest the potential of omega-3 PUFAs as a promising dietary intervention for obesity management through gut microbiota modulation. However, variability in outcomes across studies emphasizes the need for further investigation into the optimal duration, dosage and sources of omega-3 supplementation. Moreover, the synergistic effects of omega-3 PUFA supplements and lifestyle interventions, such as high-intensity interval training (HIIT), which further regulates microbial composition and improves metabolic outcomes, are also highly promising.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interaction between dietary omega-3 polyunsaturated fatty acids, obesity and gut microbiota in preclinical models: A systematic review of randomized controlled trials.\",\"authors\":\"Bing Cao, Yutong Sun, Chifong Lam, Yalin Chen, Christine E Dri, Roger S McIntyre\",\"doi\":\"10.1111/dom.16535\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Emerging research underscores the potential of omega-3 polyunsaturated fatty acids (PUFAs) in weight reduction and modulation of the gut microbiota. The current review systematically examines the effects of omega-3 PUFA supplementation on body weight regulation and gut microbiota modulation in high-fat diet (HFD)-induced obesity models. The study protocol was registered with PROSPERO (CRD42024559835). Systematic searches were conducted from database inception to May 2025 on PubMed/Embase, Web of Science and selected reference lists. A total of 32 trials were included, with 25 studies employing a HFD along with dietary omega-3 PUFA supplementation and 7 studies with a HFD prior to dietary omega-3 PUFA supplementation. Omega-3 PUFA interventions consistently demonstrated attenuation of HFD-induced weight gain and adiposity, though body weight remained elevated compared to low-fat diet controls. Omega-3 PUFA supplementation also induced significant gut microbiota compositional changes. Specifically, omega-3 PUFAs effectively reduced the Firmicutes/Bacteroidetes (F/B) ratio, reversing a hallmark feature of HFD-induced dysbiosis. Enrichment of beneficial taxa, such as Akkermansia muciniphila, Bifidobacterium and Lactobacillus, was consistently observed, correlating with enhanced short-chain fatty acid (SCFA) production, improved gut barrier integrity and reduced systemic inflammation. Concurrently, omega-3 PUFAs suppressed pathogenic bacteria, such as Desulfovibrio and Lachnoclostridium, which are associated with endotoxaemia and metabolic dysfunction. These preclinical evidence suggest the potential of omega-3 PUFAs as a promising dietary intervention for obesity management through gut microbiota modulation. However, variability in outcomes across studies emphasizes the need for further investigation into the optimal duration, dosage and sources of omega-3 supplementation. Moreover, the synergistic effects of omega-3 PUFA supplements and lifestyle interventions, such as high-intensity interval training (HIIT), which further regulates microbial composition and improves metabolic outcomes, are also highly promising.</p>\",\"PeriodicalId\":158,\"journal\":{\"name\":\"Diabetes, Obesity & Metabolism\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2025-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/dom.16535\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16535","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

新兴研究强调了omega-3多不饱和脂肪酸(PUFAs)在减轻体重和调节肠道微生物群方面的潜力。目前的综述系统地研究了在高脂肪饮食(HFD)诱导的肥胖模型中补充omega-3 PUFA对体重调节和肠道微生物群调节的影响。研究方案已在PROSPERO注册(CRD42024559835)。从数据库建立到2025年5月,在PubMed/Embase、Web of Science和选定的参考文献列表上进行了系统检索。共纳入32项试验,其中25项研究采用高脂肪饮食同时补充omega-3 PUFA, 7项研究在补充omega-3 PUFA之前使用高脂肪饮食。Omega-3 PUFA干预始终显示出hfd诱导的体重增加和肥胖的衰减,尽管与低脂饮食对照组相比,体重仍然升高。补充Omega-3 PUFA也会引起肠道微生物群组成的显著变化。具体来说,omega-3 PUFAs有效地降低了厚壁菌门/拟杆菌门(F/B)比率,逆转了hfd诱导的生态失调的一个显著特征。有益菌群,如嗜muciniphila、双歧杆菌和乳杆菌的富集,与增强短链脂肪酸(SCFA)的产生、改善肠道屏障完整性和减少全身炎症相关。同时,omega-3 PUFAs抑制致病菌,如Desulfovibrio和Lachnoclostridium,这与内毒素血症和代谢功能障碍有关。这些临床前证据表明,omega-3 PUFAs有可能通过调节肠道微生物群,作为一种有希望的饮食干预措施来控制肥胖。然而,研究结果的可变性强调需要进一步研究omega-3补充剂的最佳持续时间、剂量和来源。此外,omega-3 PUFA补充剂和生活方式干预的协同效应,如高强度间歇训练(HIIT),进一步调节微生物组成和改善代谢结果,也非常有希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Interaction between dietary omega-3 polyunsaturated fatty acids, obesity and gut microbiota in preclinical models: A systematic review of randomized controlled trials.

Emerging research underscores the potential of omega-3 polyunsaturated fatty acids (PUFAs) in weight reduction and modulation of the gut microbiota. The current review systematically examines the effects of omega-3 PUFA supplementation on body weight regulation and gut microbiota modulation in high-fat diet (HFD)-induced obesity models. The study protocol was registered with PROSPERO (CRD42024559835). Systematic searches were conducted from database inception to May 2025 on PubMed/Embase, Web of Science and selected reference lists. A total of 32 trials were included, with 25 studies employing a HFD along with dietary omega-3 PUFA supplementation and 7 studies with a HFD prior to dietary omega-3 PUFA supplementation. Omega-3 PUFA interventions consistently demonstrated attenuation of HFD-induced weight gain and adiposity, though body weight remained elevated compared to low-fat diet controls. Omega-3 PUFA supplementation also induced significant gut microbiota compositional changes. Specifically, omega-3 PUFAs effectively reduced the Firmicutes/Bacteroidetes (F/B) ratio, reversing a hallmark feature of HFD-induced dysbiosis. Enrichment of beneficial taxa, such as Akkermansia muciniphila, Bifidobacterium and Lactobacillus, was consistently observed, correlating with enhanced short-chain fatty acid (SCFA) production, improved gut barrier integrity and reduced systemic inflammation. Concurrently, omega-3 PUFAs suppressed pathogenic bacteria, such as Desulfovibrio and Lachnoclostridium, which are associated with endotoxaemia and metabolic dysfunction. These preclinical evidence suggest the potential of omega-3 PUFAs as a promising dietary intervention for obesity management through gut microbiota modulation. However, variability in outcomes across studies emphasizes the need for further investigation into the optimal duration, dosage and sources of omega-3 supplementation. Moreover, the synergistic effects of omega-3 PUFA supplements and lifestyle interventions, such as high-intensity interval training (HIIT), which further regulates microbial composition and improves metabolic outcomes, are also highly promising.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信